TRPV1 and colitis: De Schepper et al. [33] used In-Vivo techniques in conjunction with capsazepine, a TRPV1 antagonist, to demonstrate that the sensitization of the TRPV1 receptor inhibits colitis-induced abnormal motility patterns.